Is Celestica The Best AI Stock to Buy Now?
Technology and hardware business Celestica (NYSE:CLS) has seen massive upward…
Sell
32
DRUG.CX Quote, Financials, Valuation and Earnings
Last price:
$98.07
Seasonality move
:
-25.51%
Day range:
$98.07 - $98.07
52-week range:
$33.01 - $170.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
10.40x
Volume:
120
Avg. volume:
502
1-year change:
87.95%
Market cap:
$928.6M
Revenue:
--
EPS (TTM):
-$2.70
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
DRUG.CX
Bright Minds Biosciences, Inc.
|
-- | -$1.26 | -- | -200.1% | $129.33 |
|
FRX.TO
Fennec Pharmaceuticals, Inc.
|
$21.2M | -$0.03 | 68.75% | -54.08% | -- |
|
GTII.CX
Green Thumb Industries, Inc.
|
$406.9M | -$0.03 | 1.44% | -100% | $19.24 |
|
LOWL.CX
Lowell Farms, Inc.
|
-- | -- | -- | -- | -- |
|
SHRX.V
Sharp Therapeutics Corp.
|
-- | -- | -- | -- | -- |
|
WESA.X.CX
Wesana Health Holdings
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
DRUG.CX
Bright Minds Biosciences, Inc.
|
$98.07 | $129.33 | $928.6M | -- | $0.00 | 0% | -- |
|
FRX.TO
Fennec Pharmaceuticals, Inc.
|
$8.89 | -- | $327.1M | 150.93x | $0.00 | 0% | 4.35x |
|
GTII.CX
Green Thumb Industries, Inc.
|
$9.10 | $19.24 | $2.2B | 13.74x | $0.00 | 0% | 1.34x |
|
LOWL.CX
Lowell Farms, Inc.
|
$0.02 | -- | $272.2K | -- | $0.00 | 0% | 0.01x |
|
SHRX.V
Sharp Therapeutics Corp.
|
$2.25 | -- | $67.7M | -- | $0.00 | 0% | -- |
|
WESA.X.CX
Wesana Health Holdings
|
$0.0100 | -- | $200.8K | -- | $0.00 | 0% | 0.39x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
DRUG.CX
Bright Minds Biosciences, Inc.
|
0.12% | 2.958 | 0.01% | 56.27x |
|
FRX.TO
Fennec Pharmaceuticals, Inc.
|
-- | 5.822 | -- | 6.27x |
|
GTII.CX
Green Thumb Industries, Inc.
|
21.39% | 0.164 | 27.89% | 1.92x |
|
LOWL.CX
Lowell Farms, Inc.
|
-- | 1.627 | -- | 0.35x |
|
SHRX.V
Sharp Therapeutics Corp.
|
-- | -8.226 | -- | -- |
|
WESA.X.CX
Wesana Health Holdings
|
-- | -3.241 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
DRUG.CX
Bright Minds Biosciences, Inc.
|
-$19.8K | -$6.9M | -29.4% | -29.47% | -- | -$5.8M |
|
FRX.TO
Fennec Pharmaceuticals, Inc.
|
$16.8M | -$4.2M | -60.12% | -460.92% | -21.89% | -$11M |
|
GTII.CX
Green Thumb Industries, Inc.
|
$174.3M | $26.6M | 4.91% | 6.32% | 6.12% | $105.3M |
|
LOWL.CX
Lowell Farms, Inc.
|
-$1.3M | -$2.9M | -130.79% | -182.5% | -99.38% | -$1.2M |
|
SHRX.V
Sharp Therapeutics Corp.
|
-- | -$1.9M | -- | -- | -- | -$2M |
|
WESA.X.CX
Wesana Health Holdings
|
-- | -- | -- | -- | -- | -- |
Bright Minds Biosciences, Inc. vs. Competitors
-
Which has Higher Returns DRUG.CX or FRX.TO?
Fennec Pharmaceuticals, Inc. has a net margin of -- compared to Bright Minds Biosciences, Inc.'s net margin of -37.34%. Bright Minds Biosciences, Inc.'s return on equity of -29.47% beat Fennec Pharmaceuticals, Inc.'s return on equity of -460.92%.
Company Gross Margin Earnings Per Share Invested Capital DRUG.CXBright Minds Biosciences, Inc.-- -$0.97 $89.4M FRX.TOFennec Pharmaceuticals, Inc.87.2% -$0.23 $48.6M -
What do Analysts Say About DRUG.CX or FRX.TO?
Bright Minds Biosciences, Inc. has a consensus price target of $129.33, signalling upside risk potential of 31.88%. On the other hand Fennec Pharmaceuticals, Inc. has an analysts' consensus of -- which suggests that it could fall by --. Given that Bright Minds Biosciences, Inc. has higher upside potential than Fennec Pharmaceuticals, Inc., analysts believe Bright Minds Biosciences, Inc. is more attractive than Fennec Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DRUG.CXBright Minds Biosciences, Inc.5 0 0 FRX.TOFennec Pharmaceuticals, Inc.5 0 0 -
Is DRUG.CX or FRX.TO More Risky?
Bright Minds Biosciences, Inc. has a beta of -1.397, which suggesting that the stock is 239.723% less volatile than S&P 500. In comparison Fennec Pharmaceuticals, Inc. has a beta of 1.605, suggesting its more volatile than the S&P 500 by 60.515%.
-
Which is a Better Dividend Stock DRUG.CX or FRX.TO?
Bright Minds Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Fennec Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences, Inc. pays -- of its earnings as a dividend. Fennec Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG.CX or FRX.TO?
Bright Minds Biosciences, Inc. quarterly revenues are --, which are smaller than Fennec Pharmaceuticals, Inc. quarterly revenues of $19.2M. Bright Minds Biosciences, Inc.'s net income of -$7.6M is lower than Fennec Pharmaceuticals, Inc.'s net income of -$7.2M. Notably, Bright Minds Biosciences, Inc.'s price-to-earnings ratio is -- while Fennec Pharmaceuticals, Inc.'s PE ratio is 150.93x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences, Inc. is -- versus 4.35x for Fennec Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUG.CXBright Minds Biosciences, Inc.-- -- -- -$7.6M FRX.TOFennec Pharmaceuticals, Inc.4.35x 150.93x $19.2M -$7.2M
-
Which has Higher Returns DRUG.CX or GTII.CX?
Green Thumb Industries, Inc. has a net margin of -- compared to Bright Minds Biosciences, Inc.'s net margin of 26.72%. Bright Minds Biosciences, Inc.'s return on equity of -29.47% beat Green Thumb Industries, Inc.'s return on equity of 6.32%.
Company Gross Margin Earnings Per Share Invested Capital DRUG.CXBright Minds Biosciences, Inc.-- -$0.97 $89.4M GTII.CXGreen Thumb Industries, Inc.40.17% $0.50 $3.3B -
What do Analysts Say About DRUG.CX or GTII.CX?
Bright Minds Biosciences, Inc. has a consensus price target of $129.33, signalling upside risk potential of 31.88%. On the other hand Green Thumb Industries, Inc. has an analysts' consensus of $19.24 which suggests that it could grow by 111.42%. Given that Green Thumb Industries, Inc. has higher upside potential than Bright Minds Biosciences, Inc., analysts believe Green Thumb Industries, Inc. is more attractive than Bright Minds Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DRUG.CXBright Minds Biosciences, Inc.5 0 0 GTII.CXGreen Thumb Industries, Inc.8 0 0 -
Is DRUG.CX or GTII.CX More Risky?
Bright Minds Biosciences, Inc. has a beta of -1.397, which suggesting that the stock is 239.723% less volatile than S&P 500. In comparison Green Thumb Industries, Inc. has a beta of 0.855, suggesting its less volatile than the S&P 500 by 14.516%.
-
Which is a Better Dividend Stock DRUG.CX or GTII.CX?
Bright Minds Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Green Thumb Industries, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences, Inc. pays -- of its earnings as a dividend. Green Thumb Industries, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG.CX or GTII.CX?
Bright Minds Biosciences, Inc. quarterly revenues are --, which are smaller than Green Thumb Industries, Inc. quarterly revenues of $433.8M. Bright Minds Biosciences, Inc.'s net income of -$7.6M is lower than Green Thumb Industries, Inc.'s net income of $115.9M. Notably, Bright Minds Biosciences, Inc.'s price-to-earnings ratio is -- while Green Thumb Industries, Inc.'s PE ratio is 13.74x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences, Inc. is -- versus 1.34x for Green Thumb Industries, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUG.CXBright Minds Biosciences, Inc.-- -- -- -$7.6M GTII.CXGreen Thumb Industries, Inc.1.34x 13.74x $433.8M $115.9M
-
Which has Higher Returns DRUG.CX or LOWL.CX?
Lowell Farms, Inc. has a net margin of -- compared to Bright Minds Biosciences, Inc.'s net margin of -111.87%. Bright Minds Biosciences, Inc.'s return on equity of -29.47% beat Lowell Farms, Inc.'s return on equity of -182.5%.
Company Gross Margin Earnings Per Share Invested Capital DRUG.CXBright Minds Biosciences, Inc.-- -$0.97 $89.4M LOWL.CXLowell Farms, Inc.-28.98% -$0.26 $5.7M -
What do Analysts Say About DRUG.CX or LOWL.CX?
Bright Minds Biosciences, Inc. has a consensus price target of $129.33, signalling upside risk potential of 31.88%. On the other hand Lowell Farms, Inc. has an analysts' consensus of -- which suggests that it could grow by 19875.27%. Given that Lowell Farms, Inc. has higher upside potential than Bright Minds Biosciences, Inc., analysts believe Lowell Farms, Inc. is more attractive than Bright Minds Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DRUG.CXBright Minds Biosciences, Inc.5 0 0 LOWL.CXLowell Farms, Inc.0 0 0 -
Is DRUG.CX or LOWL.CX More Risky?
Bright Minds Biosciences, Inc. has a beta of -1.397, which suggesting that the stock is 239.723% less volatile than S&P 500. In comparison Lowell Farms, Inc. has a beta of 1.477, suggesting its more volatile than the S&P 500 by 47.735%.
-
Which is a Better Dividend Stock DRUG.CX or LOWL.CX?
Bright Minds Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Lowell Farms, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences, Inc. pays -- of its earnings as a dividend. Lowell Farms, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG.CX or LOWL.CX?
Bright Minds Biosciences, Inc. quarterly revenues are --, which are smaller than Lowell Farms, Inc. quarterly revenues of $4.4M. Bright Minds Biosciences, Inc.'s net income of -$7.6M is lower than Lowell Farms, Inc.'s net income of -$5M. Notably, Bright Minds Biosciences, Inc.'s price-to-earnings ratio is -- while Lowell Farms, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences, Inc. is -- versus 0.01x for Lowell Farms, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUG.CXBright Minds Biosciences, Inc.-- -- -- -$7.6M LOWL.CXLowell Farms, Inc.0.01x -- $4.4M -$5M
-
Which has Higher Returns DRUG.CX or SHRX.V?
Sharp Therapeutics Corp. has a net margin of -- compared to Bright Minds Biosciences, Inc.'s net margin of --. Bright Minds Biosciences, Inc.'s return on equity of -29.47% beat Sharp Therapeutics Corp.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DRUG.CXBright Minds Biosciences, Inc.-- -$0.97 $89.4M SHRX.VSharp Therapeutics Corp.-- -$0.17 -- -
What do Analysts Say About DRUG.CX or SHRX.V?
Bright Minds Biosciences, Inc. has a consensus price target of $129.33, signalling upside risk potential of 31.88%. On the other hand Sharp Therapeutics Corp. has an analysts' consensus of -- which suggests that it could fall by --. Given that Bright Minds Biosciences, Inc. has higher upside potential than Sharp Therapeutics Corp., analysts believe Bright Minds Biosciences, Inc. is more attractive than Sharp Therapeutics Corp..
Company Buy Ratings Hold Ratings Sell Ratings DRUG.CXBright Minds Biosciences, Inc.5 0 0 SHRX.VSharp Therapeutics Corp.0 0 0 -
Is DRUG.CX or SHRX.V More Risky?
Bright Minds Biosciences, Inc. has a beta of -1.397, which suggesting that the stock is 239.723% less volatile than S&P 500. In comparison Sharp Therapeutics Corp. has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.
-
Which is a Better Dividend Stock DRUG.CX or SHRX.V?
Bright Minds Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Sharp Therapeutics Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences, Inc. pays -- of its earnings as a dividend. Sharp Therapeutics Corp. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG.CX or SHRX.V?
Bright Minds Biosciences, Inc. quarterly revenues are --, which are larger than Sharp Therapeutics Corp. quarterly revenues of --. Bright Minds Biosciences, Inc.'s net income of -$7.6M is lower than Sharp Therapeutics Corp.'s net income of -$4.7M. Notably, Bright Minds Biosciences, Inc.'s price-to-earnings ratio is -- while Sharp Therapeutics Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences, Inc. is -- versus -- for Sharp Therapeutics Corp.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUG.CXBright Minds Biosciences, Inc.-- -- -- -$7.6M SHRX.VSharp Therapeutics Corp.-- -- -- -$4.7M
-
Which has Higher Returns DRUG.CX or WESA.X.CX?
Wesana Health Holdings has a net margin of -- compared to Bright Minds Biosciences, Inc.'s net margin of --. Bright Minds Biosciences, Inc.'s return on equity of -29.47% beat Wesana Health Holdings's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital DRUG.CXBright Minds Biosciences, Inc.-- -$0.97 $89.4M WESA.X.CXWesana Health Holdings-- -- -- -
What do Analysts Say About DRUG.CX or WESA.X.CX?
Bright Minds Biosciences, Inc. has a consensus price target of $129.33, signalling upside risk potential of 31.88%. On the other hand Wesana Health Holdings has an analysts' consensus of -- which suggests that it could grow by 2383.25%. Given that Wesana Health Holdings has higher upside potential than Bright Minds Biosciences, Inc., analysts believe Wesana Health Holdings is more attractive than Bright Minds Biosciences, Inc..
Company Buy Ratings Hold Ratings Sell Ratings DRUG.CXBright Minds Biosciences, Inc.5 0 0 WESA.X.CXWesana Health Holdings0 0 0 -
Is DRUG.CX or WESA.X.CX More Risky?
Bright Minds Biosciences, Inc. has a beta of -1.397, which suggesting that the stock is 239.723% less volatile than S&P 500. In comparison Wesana Health Holdings has a beta of -1.000, suggesting its less volatile than the S&P 500 by 200.004%.
-
Which is a Better Dividend Stock DRUG.CX or WESA.X.CX?
Bright Minds Biosciences, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Wesana Health Holdings offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Bright Minds Biosciences, Inc. pays -- of its earnings as a dividend. Wesana Health Holdings pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios DRUG.CX or WESA.X.CX?
Bright Minds Biosciences, Inc. quarterly revenues are --, which are larger than Wesana Health Holdings quarterly revenues of --. Bright Minds Biosciences, Inc.'s net income of -$7.6M is higher than Wesana Health Holdings's net income of --. Notably, Bright Minds Biosciences, Inc.'s price-to-earnings ratio is -- while Wesana Health Holdings's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Bright Minds Biosciences, Inc. is -- versus 0.39x for Wesana Health Holdings. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income DRUG.CXBright Minds Biosciences, Inc.-- -- -- -$7.6M WESA.X.CXWesana Health Holdings0.39x -- -- --
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will AI Disrupt SaaS Software Stocks?
Since January 28th, software stocks in the United States have…
Why Is Meta Stock Going Higher?
Over the last five days, shares of Instagram and Facebook…
Stock Ideas
Sell
46
Is NVDA Stock a Buy?
Market Cap: $4.3T
P/E Ratio: 36x
Sell
48
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 35x
Sell
40
Is GOOGL Stock a Buy?
Market Cap: $3.7T
P/E Ratio: 28x
Alerts
Buy
60
SNSE alert for Apr 2
Sensei Biotherapeutics, Inc. [SNSE] is up 11.23% over the past day.
Sell
47
TAYD alert for Apr 2
Taylor Devices, Inc. [TAYD] is up 1.04% over the past day.
Sell
43
AXTI alert for Apr 2
AXT, Inc. [AXTI] is down 17.29% over the past day.
